ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
C4 Therapeutics Inc

C4 Therapeutics Inc (CCCC)

6.86
-0.52
(-7.05%)
Closed July 18 4:00PM
6.8744
0.0144
(0.21%)
After Hours: 6:56PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.005.707.206.616.450.000.00 %02-
2.504.204.704.584.45-0.42-8.40 %5767/17/2024
4.002.053.202.352.6250.000.00 %051-
5.000.852.201.901.525-0.65-25.49 %85757/17/2024
6.000.751.151.050.95-0.55-34.37 %102047/17/2024
7.500.050.250.110.15-0.29-72.50 %561,0847/17/2024
9.000.050.450.050.25-0.10-66.67 %25357/17/2024
10.000.050.400.050.2250.000.00 %0131-
11.000.080.750.080.4150.000.00 %0182-
12.000.100.050.100.0750.000.00 %0148-
13.000.250.350.250.300.000.00 %0124-
14.000.220.750.220.4850.000.00 %0554-
15.000.050.050.050.050.000.00 %0179-
16.000.001.250.000.000.000.00 %00-

Professional-Grade Tools, for Individual Investors.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.000.250.050.250.150.000.00 %04-
2.500.050.050.050.050.000.00 %0214-
4.000.050.050.050.050.000.00 %0194-
5.000.300.050.300.1750.000.00 %0279-
6.001.050.251.050.650.000.00 %0410-
7.500.101.002.700.550.000.00 %0341-
9.001.902.402.402.150.000.00 %0194-
10.002.453.905.553.1750.000.00 %01-
11.003.804.302.904.050.000.00 %072-
12.004.806.006.405.400.000.00 %080-
13.005.806.307.306.050.000.00 %030-
14.006.708.100.007.400.000.00 %00-
15.007.808.308.318.050.000.00 %081-
16.008.709.300.009.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SDSTStardust Power Inc
$ 24.21
(142.10%)
5M
CETUCetus Capital Acquisition Corporation
$ 9.7856
(77.87%)
1.49M
APVOAptevo Therapeutics Inc
$ 0.5879
(75.49%)
313.2M
SHIMShimmick Corporation
$ 3.131
(51.26%)
40.45M
ADTXAditxt Inc
$ 2.32
(45.01%)
28.33M
ASLNASLAN Pharmaceuticals Ltd
$ 0.6999
(-36.95%)
2.7M
FDMT4D Molecular Therapeutics Inc
$ 18.225
(-31.87%)
6.15M
SAVACassava Sciences Inc
$ 9.57
(-29.27%)
15.16M
FIVEFive Below Inc
$ 76.50
(-25.05%)
15.12M
CGBSCrown LNG Holdings Ltd
$ 2.09
(-23.72%)
1.87M
NVDANVIDIA Corporation
$ 117.99
(-6.62%)
389M
APVOAptevo Therapeutics Inc
$ 0.5879
(75.49%)
317.61M
SQQQProShares UltraPro Short QQQ
$ 8.11
(8.71%)
175.51M
MAXNMaxeon Solar Technologies Ltd
$ 0.2432
(-3.65%)
123.1M
TSLATesla Inc
$ 248.50
(-3.14%)
115.59M

CCCC Discussion

View Posts
frans frans 16 hours ago
ut on 7.52 & 7.18
👍️0
subslover subslover 16 hours ago
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.

Details of the presentation are as follows:

Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Saturday, September 14, 2024, 2:45 – 2:50 CEST
Final Publication Number: 612MO
Session Category: Mini oral session
Session Title: Developmental therapeutics
Location: Oviedo Auditorium – Hall 3
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain, La Coruña)

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

About CFT1946

CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).
👍️0
subslover subslover 1 day ago
Strong close in after-hours trading!!!!😁
👍️0
frans frans 1 day ago
thanks
👍️ 1 🥰 1
subslover subslover 1 day ago
The shorts got wind of something in the works otherwise why all the covering? If the CEO has something juicy and meaty to announce then IMHO the shares go to the $18 -$20 mark on a sneeze. This is a great poker game and the question is who has the best hand or is it all a bluff?
👍️0
frans frans 1 day ago
should we have some news in the first days???? your opinion
👍️0
subslover subslover 1 day ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174762010
👍️0
frans frans 2 days ago
where we go ???
👍️0
frans frans 2 days ago
between 8/10 $ some nice news maybe and up up
👍️ 1 🥰 1
subslover subslover 2 days ago
I love your enthusiasm! We are heading in that direction.
👍️0
looking 4 a win looking 4 a win 2 days ago
It has to! Just for me anyway.
👍️0
frans frans 2 days ago
CCCC: I think we see next week 10 $
👍️ 1
frans frans 3 days ago
I am in hold long
👍️0
subslover subslover 3 days ago
Keep the good vibes going here, bro! :)
👍️0
subslover subslover 5 days ago
Yeah for sure!! Notice how well the stock has done since we brought in the new CEO? Was trading low at $ 4.00 and now $5.50. When looking at the short time frame he has been at the helm, this is looking good for him. We know he has got the connections and with some meaty news, we should be back well over $10.00♥️
👍️0
frans frans 5 days ago
hope they stop short now
👍️0
subslover subslover 6 days ago
Hope so!🥰
👍️0
looking 4 a win looking 4 a win 6 days ago
Reversal?
👍️0
Monksdream Monksdream 2 weeks ago
CCCC under $5
👍️0
looking 4 a win looking 4 a win 1 month ago
Amen
👍️0
subslover subslover 1 month ago
It's all fine brother, there is always a first for everything. This is a great company and we are in bed with Merck. Very few Companies can make that claim.
👍️0
looking 4 a win looking 4 a win 1 month ago
Thanks! I’ve never been lucky enough to be a part of a buyout but I’ve always dreamed I could. Honestly I don’t know jack about biotech or any other pharmaceutical monster. I just know it happens and I plan to hold and add for as long as it takes!
👍️0
subslover subslover 1 month ago
Fantastic post! This guy has the connections! I'm sick and tired of the shorts ruling here!
👍️0
looking 4 a win looking 4 a win 1 month ago
Looks like a busy guy. I’m hoping his connections at BMS or any other big pharma corp to buy C4 out.

Thanks for sharing, fingers crossed!
👍️0
subslover subslover 1 month ago
hey bro, CCC announced they brought in a new Chairman of the board and CEO. Let's hope he has the connections to stop the bleeding

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience

Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee

Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth

WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company’s aspiration to become a fully integrated biotechnology company. Ron Cooper, a global biopharmaceutical executive experienced across discovery, development and commercialization, has been appointed chairman of C4T’s Board of Directors. Bruce Downey, who served as chairman between June 2022 and June 2024, remains a member of the Board of Directors. As part of C4T’s continued Board evolution with this appointment, Glenn Dubin, who has served on C4T’s Board of Directors since 2021, has decided to step down from the Board of Directors.

“I am honored to become the next chairman of the Board of Directors of C4 Therapeutics where I expect to leverage my experience building fully integrated global biopharmaceutical companies to help C4T continue to deliver on the promise of targeted protein degradation,” said Ron Cooper. “Targeted protein degradation is a quickly evolving field with immense potential, and I am excited to work with the Board and management team to keep C4T at the forefront of this modality and help improve patients’ lives.”

Ron Cooper most recently served as president and chief executive officer of Albireo Pharma, a fully integrated, global, commercial biopharmaceutical company that was acquired by Ipsen in March 2023. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers Squibb (BMS) in roles of increasing responsibility in sales, marketing and general management, most recently serving as President, Europe. At BMS, he played a leadership role in several successful product launches, including Abilify®, Atripla®, Eliquis®, Plavix®, Sprycel® and Yervoy®. Mr. Cooper currently serves on the Board of Directors of Generation Bio.

“It has been my pleasure to serve as chairman and help C4T broaden the expertise of our Board by appointing several leaders with deep experience across clinical development, medical affairs, regulatory strategy, capital markets and commercialization. I look forward to working with Ron and our outstanding Board to help C4T capitalize on the opportunities ahead,” said Bruce Downey. “On behalf of the Board, I would like to thank Glenn Dubin for his support of C4T as he steps down so we can welcome Ron’s extensive pharmaceutical and biotechnology expertise to help lead the company in this next exciting phase. We appreciate Glenn’s contributions and wish him the best.”

“As we pursue our vision to become a fully integrated biotechnology company, we are thrilled to have Ron’s experience helping companies successfully bring products through discovery, development and commercialization,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We have an exciting path ahead and the entire C4T team remains focused on advancing our pipeline to deliver on the potential of targeted protein degradation science for patients searching for new therapies.”

https://ml.globenewswire.com/Resource/Download/a06f09c7-3115-4f0d-93c9-bb23d667fe40/ron-cooper-formal-gnw.jpg

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.

Contacts:
👍️0
looking 4 a win looking 4 a win 2 months ago
I added a lot more based on this news, still waiting but no longer adding.




https://finance.yahoo.com/news/stifel-adjusts-price-target-c4-145223168.html
👍️0
B RY B RY 2 months ago
Not adding as well. Long term hold imo.
👍️0
looking 4 a win looking 4 a win 2 months ago
This has been a massive disappointment! Normally I’d add more but I’m not seeing a reason. There was encouraging news Nelson sent me but I’m loosing faith being down every damn day!
👍️0
looking 4 a win looking 4 a win 2 months ago
Amen!
👍️0
B RY B RY 2 months ago
YW!
👍️0
looking 4 a win looking 4 a win 2 months ago
Very true, I’ve been trading for about 11 years and learned some very painful expensive mistakes, but it’s always a crap shoot. Thank man!
👍️0
B RY B RY 2 months ago
Not pushing this, just like what researched.
👍️0
B RY B RY 2 months ago
May 9,2024..."Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating"

https://finance.yahoo.com/news/stifel-adjusts-price-target-c4-145223168.html
👍️0
looking 4 a win looking 4 a win 2 months ago
Yup, that’s why I keep adding. I just get pissed being red with so much promise. I’m still keepin’ the faith!
👍️0
B RY B RY 2 months ago
"C4 Therapeutics Inc is strategically navigating its path through meticulous financial management, clinical advancements, and promising collaborations. These efforts are integral as the company continues to innovate in the challenging yet crucial area of targeted protein degradation, aiming to offer new therapeutic options for complex diseases."

https://finance.yahoo.com/news/c4-therapeutics-inc-cccc-q1-185238466.html
👍️0
looking 4 a win looking 4 a win 2 months ago
WTF?!
👍️0
looking 4 a win looking 4 a win 2 months ago
Go ahead and sell on news, I’ll just keep buying.
👍️0
looking 4 a win looking 4 a win 2 months ago
Thank you!
👍️ 1
subslover subslover 2 months ago
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned

Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins

Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024

Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.

“We are off to a strong start in 2024 with enrollment progressing well in our ongoing Phase 1/2 trials of CFT7455, now known as cemsidomide, and CFT1946. We look forward to maintaining this momentum and are on track for clinical readouts from both trials in the second half of the year,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “During the first quarter, we continued to leverage our discovery expertise as we entered into a new license and collaboration agreement with Merck KGaA, Darmstadt, Germany and delivered our first development candidate to Biogen. Together, these accomplishments further validate the excitement around our TORPEDO® platform and our ability to design innovative molecules for a range of diseases where degraders have the potential to become new therapeutic options for patients searching for treatments.”

FIRST QUARTER 2024 AND RECENT ACHIEVEMENTS

Cemsidomide (CFT7455): Cemsidomide (CFT7455) is an oral degrader of IKZF1/3 for the potential treatment of relapsed/refractory (R/R) multiple myeloma (MM) and R/R non-Hodgkin’s lymphomas (NHL).

Advanced the Phase 1/2 Clinical Trial. The dose escalation portion of the Phase 1/2 trial evaluating cemsidomide (CFT7455) in combination with dexamethasone for R/R MM and as a monotherapy for R/R NHL continues to enroll patients. For the combination with dexamethasone MM arm, the 62.5 µg dose has been declared safe and patients are enrolling at a higher dose level. Simultaneously, additional patients are enrolling in the 62.5 µg expansion cohort. For the monotherapy NHL arm, the 62.5 µg cohort has been declared safe and patients are enrolling at a higher dose level.
CFT1946: CFT1946 is an oral degrader targeting BRAF V600X mutations for the potential treatment of solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and melanoma.

Advanced the Phase 1/2 Clinical Trial. The dose escalation portion of the CFT1946 Phase 1/2 trial for BRAF V600X mutations, including NSCLC, CRC and melanoma, continues to enroll patients. The 320 mg dose has been declared safe and patients are enrolling at a higher dose level. Simultaneously, additional patients are enrolling at the 160 mg and 320 mg dose levels for pharmacokinetic, pharmacodynamic and anti-tumor activity evaluation.
Presented New Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024. In April 2024, C4T presented preclinical data highlighting superior activity of CFT1946 compared to BRAF inhibitor standard of care combinations in models of BRAF V600X NSCLC, CRC, melanoma and brain metastasis.
Trial-in-Progress Poster Accepted at European Society for Medical Oncology Congress (ESMO) Gastrointestinal (GI) Cancers Congress 2024. C4T will present a trial-in-progress poster on the CRC opportunity within the ongoing CFT1946 Phase 1/2 trial at ESMO GI 2024, taking place from June 26 to June 29, 2024.
Collaborations:

Delivered development candidate to Biogen. In April 2024, C4T earned an $8 million payment after Biogen accepted delivery of a development candidate in an undisclosed indication. Biogen is responsible for all future clinical development and commercialization for this program.
License and collaboration agreement with Merck KGaA, Darmstadt, Germany (MKDG). In March 2024, C4T entered into a license and collaboration agreement with MKDG to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline. Under the terms of the agreement, C4T received an upfront payment of $16 million. MKDG will fund C4T’s discovery research efforts. C4T has the potential to receive up to approximately $740 million in discovery, regulatory and commercial milestone payments across the collaboration. In addition, C4T is eligible for mid-single to low-double digit tiered royalties on future sales for each program.
CORPORATE UPDATES

In April 2024, Dan Powers, DO, was appointed as senior vice president, clinical development. Dr. Powers brings over 20 years of leadership experience in clinical development and medical affairs within the hematology and solid tumor space. Dr. Powers reports to C4T’s chief medical officer, Len Reyno, M.D., and is responsible for leading clinical development programs as well as supporting and executing our ongoing clinical studies.
KEY UPCOMING MILESTONES

Cemsidomide (CFT7455):

Present updated data from the ongoing Phase 1 dose escalation trial in R/R MM in 2H 2024.
Present data from the ongoing Phase 1 dose escalation trial in R/R NHL in 2H 2024.
Complete Phase 1 dose exploration in R/R MM and R/R NHL by year-end 2024.
CFT1946:

Present data from the ongoing Phase 1 monotherapy dose escalation trial in NSCLC, CRC, melanoma and other cancers with BRAF V600X mutations in 2H 2024.
FIRST QUARTER 2024 FINANCIAL RESULTS

Revenue: Total revenue for the first quarter of 2024 was $3.0 million, compared to $3.8 million for the first quarter of 2023. The decrease in revenue was primarily due to the Biogen and Calico research terms ending in 2023. In 2024, we commenced work on our new collaboration agreements with Merck Sharp & Dohme LLC (Merck) and MKDG, which were signed in December 2023 and March 2024, respectively. Total revenue for the first quarter of 2024 reflects revenue recognized under our collaborations with MKDG, Merck, Roche and Biogen, and total revenue recognized in the first quarter of 2023 reflects revenue recognized under collaboration agreements with Roche, Biogen and Calico.

Research and Development (R&D) Expense: R&D expense, net of a one-time $1.9 million restructuring charge, was $22.5 million for the first quarter of 2024. This is compared to $29.0 million for the first quarter of 2023. The reduction in R&D expense was primarily due to the prioritization of our internal discovery efforts and stopping clinical development for CFT8634, partially offset by increased clinical trial expense as cemsidomide (CFT7455) and CFT1946 continue to advance.

General and Administrative (G&A) Expense: G&A expense, net of a one-time $0.5 million restructuring charge, was $10.3 million for the first quarter of 2024. This is compared to $10.9 million for the first quarter of 2023. The decrease in G&A expense was primarily attributable to a reduction in external consulting spend.

Net Loss and Net Loss per Share: Net loss for the first quarter of 2024 was $28.4 million, compared to $34.8 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $0.41 compared to $0.71 for the first quarter of 2023.

Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of March 31, 2024 were $299.2 million, compared to $281.7 million as of December 31, 2023. The increase was primarily the result of proceeds received in January 2024 from the sale of shares of our common stock to a subsidiary of our partner Betta Pharmaceuticals and proceeds from settlement of shares under our at the market (ATM) offering arrangement, both of which were previously disclosed. These inflows were partially offset by cash used in operating activities. C4T expects that its cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to fund planned operating expenses and capital expenditures into 2027.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

About cemsidomide (CFT7455)
Cemsidomide (CFT7455) is an orally bioavailable MonoDAC™ degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Cemsidomide (CFT7455) is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show cemsidomide (CFT7455) is well tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).

About CFT1946
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including
👍️0
looking 4 a win looking 4 a win 2 months ago
Yea I read that too but for what?
👍️0
subslover subslover 2 months ago
Shareholder vote results are gonna be out on June 20th
https://www.otcmarkets.com/filing/html?id=17484687&guid=HdQ-knnQ9HXCJth
👍️0
looking 4 a win looking 4 a win 2 months ago
Anyone else know about the proxy vote that came in a few days ago?
👍️0
looking 4 a win looking 4 a win 3 months ago
MACD is at rock bottom ready for a big blast north! I’m no chart expert it look like a primo time to buy!
👍️ 1
Monksdream Monksdream 3 months ago
CCCC under $10
👍️0
subslover subslover 3 months ago
Currently, $6.53 shorts playing with fire! They will BURN!🥵
👍️0
subslover subslover 3 months ago
Short sellers love this stock and now starting to cover. It's a perfect time to buy back in IMO. Next target $18
👍️0
looking 4 a win looking 4 a win 3 months ago
Sage words, thank you.
👍️0
B RY B RY 3 months ago
👍️0
looking 4 a win looking 4 a win 3 months ago
SHIT! Need a reversal.
👍️0
looking 4 a win looking 4 a win 3 months ago
WTF is going on with this?!
👍️0

Your Recent History

Delayed Upgrade Clock